Core Scientific has completed its private offering of $460 million 3.00% Convertible Senior Notes due 2029, including the full exercise of the initial purchasers' $60 million option. The notes will accrue interest at 3.00% per annum, payable semi-annually, with maturity on September 1, 2029. The initial conversion rate is 90.9256 shares per $1,000 principal amount, representing a conversion price of approximately $11.00 per share.The company will use approximately $61.2 million of the net proceeds to repay outstanding loans under its credit agreement and $150 million to redeem all outstanding 12.50% Secured Notes due 2028. The remaining proceeds will be used for general corporate purposes, including working capital, operating expenses, capital expenditures, and potential acquisitions.The notes include provisions for early conversion under specific circumstances and redemption options after September 7, 2027, subject to certain conditions. Core Scientific can settle conversions through cash, common stock, or a combination thereof at its discretion. The notes were offered to qualified institutional buyers under Rule 144A of the Securities Act.

Core Scientific has completed its private offering of $460 million 3.00% Convertible Senior Notes due 2029, including the full exercise of the initial purchasers' $60 million option. The notes will accrue interest at 3.00% per annum, payable semi-annually, with maturity on September 1, 2029. The initial conversion rate is 90.9256 shares per $1,000 principal amount, representing a conversion price of approximately $11.00 per share.The company will use approximately $61.2 million of the net proceeds to repay outstanding loans under its credit agreement and $150 million to redeem all outstanding 12.50% Secured Notes due 2028. The remaining proceeds will be used for general corporate purposes, including working capital, operating expenses, capital expenditures, and potential acquisitions.The notes include provisions for early conversion under specific circumstances and redemption options after September 7, 2027, subject to certain conditions. Core Scientific can settle conversions through cash, common stock, or a combination thereof at its discretion. The notes were offered to qualified institutional buyers under Rule 144A of the Securities Act.